Sunday 18 October 2026
Export ABEO’s income statement to Excel — free account
Abeona Therapeutics Inc.
ABEO Healthcare Biotechnology
Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023. In the quarter to June 2026, revenue grew 225.1%, EPS fell 116.9%, free cash flow grew 17.1% and total debt fell 23.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
4.43
0.22
−4.73%
Follow ABEO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 4.02 | 3.58 | 0.00 |
P/S ratio |
— | 29.73 | 14.06 | 13.60 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (15.54) | (12.81) | (20.15) | |
P/B ratio |
— | 1.75 | 1.75 | 2.75 | |
Price to Tangible BV |
— | 1.77 | 1.77 | 2.78 | |
EV/Sales |
— | 11.47 | 5.74 | 8.52 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (1.41) | (1.33) | (2.89) | |
EV/FCF |
— | (1.28) | (1.21) | (2.71) | |
Quick Ratio |
9.43 | 6.70 | 5.64 | 6.32 | |
Current Ratio |
9.74 | 6.93 | 5.89 | 6.63 | |
Net Debt/EBITDA |
8.12 | 7.85 | 6.78 | 10.28 | |
Debt/Assets |
8.55% | 9.12% | 9.11% | 8.35% | |
Debt/Equity |
0.12 | 0.13 | 0.12 | 0.12 | |
Asset Turnover |
0.00 | 0.06 | 0.12 | 0.12 | |
Operating CF/Net income |
4.11 | 0.88 | 1.16 | 0.87 | |
Capex/Depreciation |
(2.84) | (1.06) | (1.08) | (0.57) | |
Interest Coverage |
(26.66) | (25.92) | (27.75) | (19.62) | |
Research and Development Expense of Revenue |
0.00% | 123.84% | 109.58% | 44.12% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 346.53% | 223.65% | 139.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 47.21% | (27.86%) | 76.93% | |
Graham Net Nets |
— | 0.52 | 0.51 | 0.32 | |
Graham Number |
— | 9.41 | 8.49 | 0.00 | |
Earnings Yield |
— | 24.86% | 27.90% | (18.93%) | |
Free Cash Flow Yield |
— | (30.21%) | (33.60%) | (23.12%) | |
Revenue per Share |
0.00 | 0.10 | 0.15 | 0.20 | |
Operating CF per Share |
(0.39) | (0.34) | (0.35) | (0.31) | |
Capex per Share |
(0.05) | (0.02) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.44) | (0.36) | (0.37) | (0.32) | |
Cash per Share |
3.82 | 3.61 | 2.97 | 2.57 | |
Shareholders Equity per Share |
3.16 | 3.01 | 2.56 | 2.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.16 | 3.01 | 2.56 | 2.24 | |
Free Cash Flow |
(23.71) | (19.11) | (20.74) | (17.97) | |
Working Capital |
193.95 | 175.34 | 151.94 | 139.77 | |
Capital Expenditures |
(2.52) | (1.15) | (0.93) | (0.48) | |
Net Current Asset Value |
156.27 | 144.55 | 129.43 | 113.13 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.21 | 0.11 | 0.04 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.61 | 4.18 | 4.16 | 5.76 | |
Average Payables |
4.36 | 5.67 | 4.54 | 5.17 | |
Average Inventory |
— | — | — | 4.30 | |
Average Assets |
175.84 | 164.25 | 148.93 | 212.87 | |
Average Common Equity |
108.50 | 101.62 | 93.17 | 145.82 |
Columns are period end dates